Literature DB >> 10866821

Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide.

C Loske1, A Gerdemann, W Schepl, M Wycislo, R Schinzel, D Palm, P Riederer, G Münch.   

Abstract

beta-Amyloid deposits, hallmarks of Alzheimer's disease, contain both sugar-derived 'advanced glycation end products' (AGEs) and copper and iron ions. Our in vitro experiments using synthetic beta-amyloid peptide and glucose or fructose show that formation of covalently cross-linked high-molecular-mass beta-amyloid peptide oligomers is accelerated by micromolar amounts of copper (Cu+, Cu2+) and iron (Fe2+, Fe3+) ions. Formation of these covalent AGE cross-links can be inhibited by capping agents of amino groups, redox-inactive metal chelators and antioxidants, suggesting that these drugs may be able to slow down the formation of insoluble beta-amyloid deposits in vivo and possibly the progression of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866821     DOI: 10.1046/j.1432-1327.2000.01452.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  26 in total

1.  Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  Methods Mol Biol       Date:  2010

2.  Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-κB pathway in a transgenic mouse model of Alzheimer's disease.

Authors:  Chun-Yan Wang; Jing-Wei Xie; Ye Xu; Tao Wang; Jian-Hui Cai; Xu Wang; Bao-Lu Zhao; Li An; Zhan-You Wang
Journal:  Antioxid Redox Signal       Date:  2013-05-03       Impact factor: 8.401

3.  Glycoxidized particles mimic lipofuscin accumulation in aging eyes: a new age-related macular degeneration model in rabbits.

Authors:  Tsutomu Yasukawa; Peter Wiedemann; Stefan Hoffmann; Johannes Kacza; Wolfram Eichler; Yu-Sheng Wang; Akiko Nishiwaki; Johannes Seeger; Yuichiro Ogura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-04       Impact factor: 3.117

Review 4.  The link between iron, metabolic syndrome, and Alzheimer's disease.

Authors:  Edna Grünblatt; Jasmin Bartl; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2010-06-17       Impact factor: 3.575

5.  LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.

Authors:  J L Figarola; S Scott; S Loera; C Tessler; P Chu; L Weiss; J Hardy; S Rahbar
Journal:  Diabetologia       Date:  2003-07-05       Impact factor: 10.122

6.  Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors.

Authors:  Michela Guglielmotto; Luca Giliberto; Elena Tamagno; Massimo Tabaton
Journal:  Front Aging Neurosci       Date:  2010-02-09       Impact factor: 5.750

7.  Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  J Nanoneurosci       Date:  2009-06-01

Review 8.  Oxidative stress in Alzheimer disease.

Authors:  Alejandro Gella; Nuria Durany
Journal:  Cell Adh Migr       Date:  2009-01-13       Impact factor: 3.405

Review 9.  Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetes.

Authors:  Gary E Gibson; Joseph A Hirsch; Rosanna T Cirio; Barry D Jordan; Pasquale Fonzetti; Jessica Elder
Journal:  Mol Cell Neurosci       Date:  2012-09-13       Impact factor: 4.314

10.  Involvement of Maillard reactions in Alzheimer disease.

Authors:  V Prakash Reddy; Mark E Obrenovich; Craig S Atwood; George Perry; Mark A Smith
Journal:  Neurotox Res       Date:  2002-05       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.